文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Objective Response by mRECIST Is an Independent Prognostic Factor of Overall Survival in Systemic Therapy for Hepatocellular Carcinoma.

作者信息

Kudo Masatoshi

机构信息

Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

出版信息

Liver Cancer. 2019 Mar;8(2):73-77. doi: 10.1159/000497460. Epub 2019 Feb 27.

DOI:10.1159/000497460
PMID:31019898
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6465712/
Abstract
摘要

相似文献

[1]
Objective Response by mRECIST Is an Independent Prognostic Factor of Overall Survival in Systemic Therapy for Hepatocellular Carcinoma.

Liver Cancer. 2019-3

[2]
Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.

J Hepatol. 2017-1-26

[3]
EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.

Clin Cancer Res. 2014-2-3

[4]
EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization.

J Hepatol. 2011-4-15

[5]
Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis.

PLoS One. 2015-7-31

[6]
EASL and mRECIST responses are independent predictors of survival in hepatocellular carcinoma patients treated with cryoablation.

Eur J Gastroenterol Hepatol. 2013-5

[7]
mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.

Liver Int. 2017-2-2

[8]
Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.

Oncology. 2012-8-11

[9]
Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma.

Acta Radiol. 2015-12

[10]
Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma.

Liver Cancer. 2014-10

引用本文的文献

[1]
Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and Transarterial Chemoembolization to Achieve Synergistic Effects.

Liver Cancer. 2022-10-6

[2]
Study on the changes of CT texture parameters before and after HCC treatment in the efficacy evaluation and survival predication of patients with HCC.

Front Oncol. 2022-10-28

[3]
Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma.

Cancers (Basel). 2022-1-10

[4]
Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma.

Cancers (Basel). 2022-1-4

[5]
Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.

Liver Cancer. 2021-4-20

[6]
Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update.

Liver Cancer. 2020-12

[7]
Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma.

JGH Open. 2020-4-11

[8]
Evaluation of liver tumour response by imaging.

JHEP Rep. 2020-4-28

[9]
Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment.

Cancers (Basel). 2020-3-25

[10]
Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma.

Liver Cancer. 2020-1

本文引用的文献

[1]
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.

Lancet Gastroenterol Hepatol. 2018-4-7

[2]
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.

J Hepatol. 2018-7

[3]
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

Lancet. 2018-3-24

[4]
Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.

J Hepatol. 2017-1-26

[5]
mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.

Liver Int. 2017-2-2

[6]
Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.

BMC Res Notes. 2015-10-26

[7]
Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis.

PLoS One. 2015-7-31

[8]
Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.

Dig Dis. 2014

[9]
Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.

Oncologist. 2014-4

[10]
Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.

Cancer. 2011-6-28

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索